Stream Neuroscience

Stream Neuroscience is a private biotechnology company dedicated to developing novel small molecule therapies for difficult-to-treat neurological disorders, with a primary focus on epilepsy and neurodegeneration. The company utilizes its patented MitoREAD drug discovery platform, which integrates neurometabolism and machine learning to identify intracellular targets that regulate multiple biological pathways. Stream's lead program, SN-2000, is a selective phosphodiesterase 4B (PDE4B) inhibitor designed to increase cyclic adenosine monophosphate (cAMP) levels, thereby stabilizing neuronal signaling and potentially improving cognitive function. In addition to its epilepsy pipeline, the company is advancing discovery-stage programs targeting the phosphoinositide 3-kinase (PI3K) pathway to address excessive neuronal signaling. Founded by academic experts from the University of Calgary, Stream Neuroscience has secured significant seed and non-dilutive funding to support its mission of restoring brain health through intracellular modulation.